Opiant Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 10, 2022
Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) will release its financial results for Q1 2022 on May 10, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) will release its financial results for Q1 2022 on May 10, 2022. The announcement will occur after market close, followed by a conference call at 4:30 PM ET. Investors can access the call at 1-877-407-0792 (U.S.) or 1-201-689-8263 (International) and join the live webcast online. Opiant is known for developing NARCAN® Nasal Spray and is focused on creating new treatments for addiction and drug overdose.
Details
News Market Reaction – OPNT
The recorded move for OPNT in the trading session of this news was -6.37%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SANTA MONICA, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, will report its financial results for the first quarter ended March 31, 2022, after the financial markets close on Tuesday, May 10, 2022.
The Company’s management team is scheduled to host a conference call and webcast with slides at 4:30 p.m. ET on Tuesday, May 10, 2022. To access the call, please dial 1-877-407-0792 in the U.S. or 1-201-689-8263 outside the U.S. and provide the conference ID number: 13728852. To access the live webcast, please visit https://viavid.webcasts.com/starthere.jsp?ei=1542632&tp_key=dabaa0a667. Following the live webcast, an archived version of the call will be available on the website.
Tuesday May 10 @ 4:30 pm ET
| Domestic: | 1-877-407-0792 |
| International: | 1-201-689-8263 |
| Conference ID: | 13728852 |
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1542632&tp_key=dabaa0a667 |
About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.
For more information visit: www.opiant.com.
For Media and Investor Inquiries:
Ben Atkins, Opiant
(310) 598-5410
batkins@opiant.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.